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Abstract: Background: Platelet-Rich Plasma (PRP) is a blood component used for the biological treatment in many fields of 
regenerative medicine. The term PRP is currently applied to numerous blood components with different cellular and protein 
compositions. The optimal platelet concentration and the best technique for preparing PRP have not yet been defined and it is, 
therefore, important to understand the specific biological roles of the individual components. The aqueous part of PRP is plasma, 
which is an acellular component with containing proteins that are important for tissue regeneration. Objective: This preclinical 
study evaluated the biological characteristics and effects on proliferation (in an in vitro model) of a blood component 
Protein-Enriched Filtered PRP (PEFPRP) obtained through the ultrafiltration of low-concentration PRP and compared these 
effects with those of a standard PRP and other blood components preparation. Method: PEFPRP is a plasma enriched obtained by 
ultrafiltration of a plasma with low concentration platelets and its effects have been compared with those of a standard PRP and 
other blood components preparation. Result and Conclusion: PEFPRP provides a high concentration of proteins which have an 
important accessory function in in-vitro proliferation and could be highly significant in-vivo, accelerating tissue regeneration. 
Keywords: Platelet-rich Plasma, Plasma Proteins, Ultrafiltration, Growth Factors 
 
1. Introduction 
It has been 10 years since we published "Not every PRP-gel 
is born equal. Evaluation of growth factor (GF) availability for 
tissues through four PRP-gel preparations: Fibrinet®, 
RegenPRP-KIT®, Plateltex® and one manual procedure" [1] 
one of the first works comparing products obtained through 
different methods of preparing Platelet-Rich Plasma (PRP). 
Since then the world of non-transfusion blood components has 
changed greatly and many different preparation techniques 
have been introduced, which have led to similar but also very 
different blood components [2]. Our work concluded that even 
similar methods of preparing PRP resulted in different GF 
recovery and release kinetics; although it is unclear whether 
these observable differences are important for clinical 
management, these findings do highlight the importance of the 
method of preparation used, since the very different technical 
characteristics (disparity of tubes, centrifugation force, 
gel-inducing enzyme) have variable effects on the final 
product and on the release kinetics of platelet GF and other 
molecules [3-5]. The purpose of PRP-based therapies is to 
promote tissue regeneration with a "platelet molecule load", so 
different release characteristics can alter the final clinical 
outcome. During our initial studies, we hypothesized that the 
diversity in transfer of GF from PRP prepared in different 
ways could be interesting if exploited for specific treatments 
depending on the complexities of the lesions or the 
pathologies and their consequent greater or lesser requirement 
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for regenerative stimuli to accelerate the healing process [6-8]. 
This approach of "tailor-made" treatment for a specific 
pathology is currently a new concept, shared by many authors, 
and is undoubtedly related to the availability of a broad variety 
of blood components for non-transfusion use which differ in 
cell composition, plasma quantity and fibrin content [9, 10]. In 
1998 Marx et al. described PRP as a "simple" concentrate of 
platelets re-suspended in plasma [11] but we now have a 
multitude of PRP that contain different concentrations of 
platelets as well as fibrin and/or leucocytes [12]. The 
regenerative action of PRP is generally linked to the secretoma 
of the cellular component (platelets and leucocytes), which 
consists primarily of platelet GF and pro- and 
anti-inflammatory molecules of both platelet and leucocyte 
origin and is discharged into the plasma component [13]. The 
aqueous, liquid part of PRP is therefore the plasma, which 
does not convey cells, but does contain important proteins 
such as fibrinogen, fibronectin, vitronectin, thrombospondin, 
gelsolin and many others with adhesive, chemotactic, 
immunoregulatory and also anti-microbial properties, which 
are important for extracellular matrix reconstruction and 
healing [14, 15]. Having a blood component for 
non-transfusion use, protein-enriched filtered PRP (PEFPRP), 
which in addition to being a concentrate of cellular factors also 
provides a plasma protein concentrate at the site of the lesion, 
could be advantageous to deliver not only pro-angiogenic, 
proliferative and immunoregulatory factors, but also basic 
molecules for the reconstruction of the extracellular matrix 
and thus help the restoration of the natural scaffold necessary 
for the formation of new tissue [16]. PEFPRP is a conceptually 
new product obtained through the filtration of 
low-concentration PRP [17, 18]. The main objective of this 
work is to assess the biological characteristics of PEFPRP and 
compare its proliferative activity with that of conventional 
PRP and other blood components, using cultured fibroblasts as 
an in vitro model. 
2. Material and Methods 
2.1. Blood Collection 
Blood was obtained from ten healthy donors, compatible 
group (A and 0), who gave prior consent to the use of their 
biological material for research purposes. From each donor, 14 
mL of blood were collected into ACD- A and 5 mL were 
collected without anticoagulant. The blood was prepared in 
two different groups: 140 mL in ACD-A for PRP and PEFPRP, 
50 mL for SERUM 
2.2. PRP and PEFPRP 
Of the 140 mL of blood collected into ACD-A, 110 mL 
were distributed into two specific devices (55 mL for each) 
and automatically separated (CPunT system; Eltek Group SpA, 
Hone, Italy) to obtain 40 mL of PRP (PRP 0.4) at a platelet 
concentration of 0.4 x 10
6
/µL (±5%) (ABX Micro ES 60; 
Horiba Medical Group, Montpellier, France). The PRP 0.4 
was divided into two parts. One half, 20 mL, was subjected to 
a second centrifugation (1200 g for 10’ - Heraeus Megafuge 
16; ThermoFisher Scientific, Dreieich, Germany) in order to 
prepare aliquots of platelets at different concentrations: 0.6 
(PRP 0.6), 0.8 (PRP 0.8), 1.0 (PRP 1.0), 1.2 (PRP 1.2), 1.4 (PRP 
1.4), 1.6 (PRP 1.6), 1.8 (PRP 1.8) and 2.0 (PRP 2.0) x 10
6
 
platelets/µL. The second part, 20 mL, was ultrafiltrated for 
PEFPRP. To obtain the PEFPRP we used a protein and blood 
component concentrator, PROSMART
TM
 (Medica Group SpA, 
Medolla, Italy). This medical device (CE) exploits thin 
MediSulfone® fibres (average fibre cut-off 15 kDa, average 
porosity 5 nm) to make a platelet concentrate (about 4- to 5-fold 
the basal value) rich in proteins. Following the ultrafiltration 
step, platelets were morphologically intact and not aggregated 
(as determined by visual examination with a Leica DFC 295 
microscope, Wetzlar, Germany) and functional (as determined 
by a Platelet Function Analyser; Siemens, Munich, Germany). 
The ultrafiltration/concentration of blood components was 
performed according to the manufacturer's instructions. 
Proteins and platelets are concentrated by the effect of 
removing part of the aqueous component of plasma. The 
concentrated product (about 8 mL) is recovered by suction 
through the same input path to the filter. 
2.3. Other Blood Components 
50 mL of whole blood without anticoagulant were 
centrifuged to obtain SERUM and 30 mL of blood collected 
into ACD-A were used to produce plasma (PL). PL was 
separated into two lots: 10 mL were ultrafiltrated to obtain 
protein-enriched filtered plasma (PEFPL) and the remaining 5 
mL were stored untreated. Using an ADVIA 2400 (Siemens, 
Munich, Germany), total proteins were assayed in all products 
subjected to ultrafiltration (before and after) and also 
post-filtration, on the liquid (water) removed. 
2.4. Identification of Proteins 
The samples were then subjected to denaturation with 
trifluoroethanol, reduction with dithiothreitol 200 mM, 
alkylation with iodoacetamide 200 mM and complete protein 
digestion with Trypsin/Lys-C (Promega, Madison, WI, USA). 
The peptide digests were desalted on a Discovery® DSC-18 
solid phase extraction (SPE) 96-well plate (25 mg/well) 
(Sigma-Aldrich Inc., St. Louis, MO, USA). The samples were 
spiked with 2 µL of stable isotope-labelled peptide standard 
(DPEVRPTSAVAA Val- 13C515N1 at V10; Cellmano 
Biotech Ltd., Anhui, China) before liquid chromatography 
with tandem mass spectrometry (LC-MS/MS) using a 
micro-liquid LC system (Eksigent Technologies, Dublin, 
USA). For identification purposes the samples were subjected 
to data-dependent acquisition: the MS analysis was performed 
using a mass range of 100-1500 Da (time-of-flight scan with 
an accumulation time of 0.25 s), followed by a MS/MS 
product ion scan from 200 to 1250 Da (accumulation time of 
5.0 ms) with the abundance threshold set at 30 cps (35 
candidate ions can be monitored during each cycle). Two 
data-dependent and three data-independent acquisitions were 
performed. 
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2.5. Cell Culture and Medium 
For growth evaluation, human primary fibroblasts (Normal 
Human Dermal Fibroblast adult skin, NHDF; Lonza, 
Walkersville, MD, USA) were seeded (5x10
3
 cells) in 96-well 
culture plates in a complete medium (Invitrogen Corporation, 
Carlsbad, CA, USA). The following day, the cells were starved 
in FBS (Foetal Bovine Serum)-free Dulbecco’s modified 
Eagle’s medium for 72 h and then incubated with 10% blood 
component preparations: PL, PEFPL, PRP (from 0.4 to 2.0), 
PEFPRP, and SERUM. Cell proliferation was determined at 6 
days after treatment with a colorimetric method, using an MTS 
Assay Kit (CellTiter 96 Aqueous One Solution cell 
proliferation assay, Promega, San Luis Obispo, CA, USA) and 
the contents of the plates were read at 490 nm with a microplate 
reader (Microplate Reader - BioTeck Instruments, Winooski, 
WT, USA). 
2.6. Determination of Growth Factor Concentrations 
The concentrations of vascular endothelial growth factor 
(VEGF), epidermal growth factor (EGF), and platelet-derived 
growth factor (PDGF-bb) were measured in PL, PEFPL, PRP, 
PEFPRP, SERUM using immunoassays (Quantikine
®
 ELISA 
kits, R&D Systems, Abingdon, UK) and each sample was 
treated in according to the manufacturer’s protocol. 
2.7. Protein Database Search and Statistical Analysis 
The data-dependent acquisition files were searched using 
Protein Pilot software v. 4.2 (Sciex, Concord, Canada) and 
Mascot v. 2.4 (Matrix Science Inc., Boston, MA, USA). The 
UniProt Swiss-Prot reviewed database containing human 
proteins (version 2015.07.07, containing 42,131 sequence 
entries) was used and a target-decoy database search was 
performed. The false discovery rate was set at 1%. Data were 
analysed with Graph Pad Prism version 8.3.1 (Graph Pad 
Software Inc., San Diego, CA, USA). One-way analysis of 
variance (ANOVA) was used to analyse the effect of the 
different blood components. 
3. Results 
We first analysed the impact of PRP-released factors with 
different concentrations of platelets (Figure 1) on the 
proliferation of human fibroblasts PRP [19, 20], ss as standard 
protocol (see other items), with platelet counts from 0.4 x 10
6
 
to 2.0 x 10
6
/mL was applied onto cultured human fibroblasts 
in FBS-free medium (10% vol/vol in cell culture medium); the 
increase in proliferation was compared to that of cells cultured 
in 10% FBS (Control) and PL at 6 day [21]. 
 
Figure 1. Figure illustrating the manufacturing process and sample preparation from whole-blood. PL: plasma; PRP: Platelet-Rich Plasma; PEFPL: 
Protein-Enriched Filtered Plasma; PEFPRP: Protein-Enriched Filtered PRP. 
 
Figure 2. Effect of Platelet-Rich Plasma (PRP) with increasing platelet 
concentration (10% vol/vol as a supplement in culture medium) at 6 days of 
culture. Experiments were performed in 5 times and data (O. D.: optical 
density) representative of a minimum of 5 independent experiments are 
shown. 
As expected, all PRP conditions induced an increase of 
fibroblast growth which was comparable to that measured in 
10% of other blood components (Figure 2). At 6 days there 
were differences between all PRP conditions and other blood 
components: PRP increased NHDF proliferation by 1.4- to 
2.2-fold, compared to the Control and PL. The number of the 
platelets in PRP induces increase of proliferation from 0.4 to 
1.0, but from 1.2 to 2.0 the proliferation activity increased less 
and a plateau effects is observed. Then best condition was 10% 
PRP 1.0, which produced a 2.2-fold increase in fibroblast 
proliferation. 
Next we analysed the impact of the best PRP (PRP 1.0) and 
other blood components on human fibroblasts, to further 
investigate whether PEFPRP was better than PRP 1.0 at 
promoting growth. Fibroblast growth was detected and 
quantified at 6 days of incubation with culture medium with 
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medium); PRP 1.0, PEFPRP and SERUM increased fibroblast 
growth by 1.2- and 1.7-fold compared to the Control [22, 23] 
(Figure 3). The best result (1.7-fold increase in proliferation) 
was obtained with culture medium with 10% PEFPRP. 
 
Figure 3. Comparison between the effect of different blood components, 
added as a supplement in culture medium, on proliferation of human 
fibroblasts at 6 days; “Control” is fibroblast proliferation in the standard 
condition (medium with 10% foetal bovine serum). All evaluations were 
performed 8 times with 8 independent experiments. 
Since ultrafiltration increases the concentration of proteins 
present in PRP and PL, we next measured the total amount of 
proteins present before and after filtration [24] (Table 1). 
Table 1. Quantification of total proteins (g/dL) in Plasma (PL) and 
Platelet-Rich Plasma (PRP 0.4) before and after ultrafiltration. The 
increment of total proteins in PEF is at least double the value at baseline. 
 PL PEFPL PRP 0.4 PEFPRP 
g/dL 6.1±0.1 15.7±1.2 6±0.2 18±1.4 
The concentrations of plasma proteins in the PEF products 
(PEFFL and PEFPRP) were higher (2.5- to 3-fold) than in their 
corresponding unfiltered products (PL and PRP 0.4). We also 
evaluated whether the concentration of some GF varied 
depending on the biological preparation; to do this, we 
measured the amounts of VEGF, EGF, and PDGF-bb in PL, 
PEFPL, PRP, PEFPRP and SERUM [25] (Table 2). The amounts 
of VEGF, EGF and PDGF-bb were significantly increased in 
PEFPRP compared to the amounts in other blood components 
and were higher in PRP and SERUM than in PL and PEFPL, 
(suggesting that most derived from platelets): it is, therefore, 
very interesting that PEFPRP contains all the GF present in the 
starting blood component (PRP 0.4) [26, 27]. 
Table 2. Mean concentrations (pg/mL)±standard deviation of vascular 
endothelial growth factor (VEGF), epidermal growth factor (EGF), and 
platelet-derived growth factor (PDGF-bb) detected in the different blood 
components studied. All assays were performed in triplicate. 
pg/mL VEGF EGF PDGF 
PL 246±4 109±54 2597±634 
PEFPL 241±49 147±102 4221±413 
PRP 1.0 585±75 2670±185 24526±185 
PEFPRP 786±175 3965±496 115675±6088 
SERUM 405±21 1444±369 14493±1443 
A label-free proteomic approach using sequential window 
acquisition of all theoretical mass spectra (SWATH)-MS 
technology was employed in order to quantify the relative 
abundance of the proteins in each sample [28, 29]. The statistical 
analysis showed that 30 proteins were enriched in the PEFPRP 
with respect to PRP. Table 3 lists these proteins, classified based 
on the biological process in which they are involved. 
Table 3. Modulated proteins in PEFPRP prepared with the immunodepletion of 
abundant proteins. The modulated proteins were classified in order to 
highlight the biological processes and the protein classes enriched during the 
preparation of PEFPRP. Cytoskeletal organisation, regulation of proteolysis 
and cellular response to cytokine stimulus are the activities upregulated and 
most represented in this new blood component. 
Pro-inflammation CBG, GSTO1 
Anti-inflammation CO5, AACT, GSTO1, CBPN 
Wound healing 
ACTB, ACTG, FCN3, TNL1, HSP7C, ACTC, SPTC2, 
CBPN, GELS, ENOA, VTNC, ACTC, COF1, CAP1, 
ALDOA PROF1, PEDF, FCN3, AACT 
Clot stabilisation FA12, FIBG, F13, FIBB 
Anti-microbial PRGP2 
4. Discussion 
Platelets, blood components and their derivatives have 
numerous advantages as biological products for the treatment 
of many pathologies. The advantages of their therapeutic use 
include the fact that they are autologous products, easily 
prepared, cause minimal complications, and have a broad 
range of potential actions. Cells (platelets and leucocytes) and 
the liquid portion (plasma) of PRP and other products 
contemporaneously release many proteins and factors with 
different anabolic and catabolic functions that reduce 
inflammation and promote angiogenesis and tissue 
regeneration. The right number of platelets in PRP or platelet 
derivatives has been debated for many years: the platelet 
concentration must be at least three or four times higher the 
baseline value in order to provide a ‘therapeutic dose’ of 
platelet factors [30, 31]. We observed the effect of different 
PRP on a fibroblast culture model. PRP with different 
concentrations of platelets generally had an incremental effect 
on fibroblast proliferation, although this positive effect was 
not immediate, showing a biphasic trend: in fact, after having 
been starved of FBS, the stimulation of fibroblast proliferation 
at 6 days was evident. In vitro experiments have shown that 
proliferation of human fibroblast is enhanced by addition of 
PRP at different concentration to the culture medium, but it 
would seem that the effect is not directly related to platelets 
numbers, indeed after PRP 1.0 the variances between the 
different PRP concentration was minimal. The amounts of 
bioactive molecules released by platelets are roughly 
proportional to the platelet concentration in the preparation 
and the effect on cell growth of different platelet 
concentrations in PRP (according to previously published data 
by several authors) is not linear [32]. For this study we chose 
the best PRP concentration (PRP 1.0) and evaluated the effect 
of PEFPRP at the same platelet concentration. The technique of 
ultrafiltration of low-concentration PRP (PRP 0.4) is a new 
possible alternative to centrifugation to increase the 
concentration of platelets and, compared to this latter, is less 
aggressive to the platelets, better preserving their structure and 
function. In addition our results of the analysis of the eluate, 
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PEFPRP, demonstrated that other important biomolecules are 
concentrated, such as total plasma proteins and GF. Platelet 
derivatives are used to provide GF concentrates that are able to 
induce and accelerate the healing process. However, together 
with GF, PRP contains hundreds of plasma proteins that are 
more abundant. Much research has been conducted to study 
platelets and derivatives, but only a few have adopted a 
proteomic approach to characterise PRP [33]. The highest 
concentration of proteins was found in PEFPRP as this product 
contains plasma and platelet molecules. To investigate the role 
of these proteins in tissue regeneration we also applied 
proteomic techniques to PEFPRP to analyse the structural and 
functional pathways of the proteins. PEFPRP contained 30 
upregulated proteins grouped into those involved in 
cytoskeleton organisation, regulation of proteolysis and 
cellular response to cytokine stimulus. To classify these 
proteins by function we defined keywords, focusing on the 
tissue healing process and identified subgroups classified by 
their functions: pro-inflammatory, anti-inflammatory, wound 
healing, clot stabilisation, anti-microbial and other plasma 
components such as those of the complement system, 
cell-matrix adhesion and immunoglobulins [34, 35]. Our 
results suggest that the plasma protein concentrate in PEF had 
an important role: gene ontology classification showed that 
there is an enrichment of several biological processes such as 
the immune system and biological adhesion, but also of 
enzyme modulator and signalling proteins. Key components 
for the regeneration or replacement of tissue are GF, such as 
VEGF, EGF and PDGF-bb, which provide vital stimuli for 
cell recruitment, proliferation, morphogenesis and 
differentiation [36, 37]. In accordance with previous studies 
we found that specific GF were present in variable 
concentrations depending on the biological preparation. 
Interestingly we observed that the amounts of GF were greater 
in cellular blood components, SERUM, PRP and PEFPRP and, 
in particular, in PRP and PEFPRP because these have higher 
platelet concentrations and in PEFPRP because of the 
ultrafiltration process. This method of concentrating PRP is 
better than centrifugation because the resulting eluate contains 
all the plasma proteins and platelets. In brief, we have 
provided further evidence that PEFPRP can exert a proliferative 
stimulus on fibroblasts, increasing the number of the cells in 
culture, and thereby contribute to improving tissue 
regeneration. The combination of plasma proteins and platelet 
proteins, both concentrated, may facilitate tissue regeneration. 
In fact, our results support the hypothesis of a beneficial action 
not only of GF, but of plasma proteins too, which are present 
in larger quantities in PEFPRP. The clot stabilisation and 
cell-matrix adhesion proteins (fibrinogen, fibrin, fibronectin, 
and thrombin) contribute to creating the three-dimensional 
environment that is a critical condition for cell-cell and 
protein-protein interactions as well as for tissue regeneration 
and healing [38]. 
5. Conclusion 
PEFPRP produced by ultrafiltration of PRP triggers greater 
cell growth than any other product tested. The probable less 
stress caused to the platelets during filtration produces a 
notable increase in the available fraction of GF. Tests 
performed cannot establish the real role of the high 
concentrations of proteins obtained by filtration; however, the 
plasma proteins, which increase moderately and probably 
have an accessory function in in vitro proliferation, may be 
highly relevant in vivo, in which the interactions between 
numerous plasma proteins, cells and the extracellular matrix 
of the tissues to be repaired play an important role in 
accelerating tissue regeneration. 
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